Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
The in vitro activity of RO 23-6240 was compared with that of norfloxacin, ofloxacin and ciprofloxacin as well as four other antimicrobial agents against 345 recent clinical isolates. The MICs of RO 23-6240 against Enterobacteriaceae and Acinetobacter anitratum was less than or equal to 0.5 mg/l. At the same concentration of the compound 90% of staphylococci were inhibited. Against Enterococcus faecalis and Pseudomonas aeruginosa RO 23-6240 proved less active, having MIC90 values of 4.0 mg/l and 8.0 mg/l, respectively. Enterobacteriaceae and staphylococci strains that were resistant to piperacillin, cefotaxime or tobramycin were susceptible to the compound. In general the activity of RO 23-6240 was comparable to those of norfloxacin and ofloxacin, but less than that of ciprofloxacin.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects; D013293:Enterococcus faecalis / Q000187:drug effects; D016576:Fleroxacin; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D010078:Oxazines; D002939:Ciprofloxacin; D015242:Ofloxacin; D009643:Norfloxacin; D016576:Fleroxacin